• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

登革2型疫苗:在埃及伊蚊中的口服感染、传播及无证据表明病毒在蚊体内回复突变

Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti.

作者信息

Miller B R, Beaty B J, Aitken T H, Eckels K H, Russell P K

出版信息

Am J Trop Med Hyg. 1982 Nov;31(6):1232-7. doi: 10.4269/ajtmh.1982.31.1232.

DOI:10.4269/ajtmh.1982.31.1232
PMID:7149108
Abstract

The dengue-2 vaccine virus (S-1), and its parent virus (PR-159), were compared for their ability to infect orally, to replicate in, and subsequently to be transmitted by Aedes aegypti mosquitoes. The vaccine virus was markedly less efficient in its ability to infect mosquitoes orally. After ingesting infectious bloodmeals containing 3, 7 to 8.2 log10MID50/ml of the respective viruses, 56% (220/396) of the mosquitoes became orally infected with the parent virus contrasted with 16% (66/397) for the vaccine virus. None of the 16 infected mosquitoes transmitted the vaccine virus, while 14% (3/22) of the mosquitoes transmitted the parent virus. The vaccine virus remained temperature-sensitive (restrictive temperature 39 degrees C) after orally infecting and replicating in Ae. aegypti mosquitoes.

摘要

对登革2型疫苗病毒(S-1)及其亲代病毒(PR-159)在经口感染、在埃及伊蚊体内复制以及随后通过埃及伊蚊传播的能力方面进行了比较。疫苗病毒经口感染蚊子的能力明显较低。在摄入含有3、7至8.2 log10半数感染剂量(MID50)/毫升各自病毒的感染性血餐后,56%(220/396)的蚊子经口感染亲代病毒,相比之下,疫苗病毒感染率为16%(66/397)。16只感染的蚊子中没有一只传播疫苗病毒,而14%(3/22)的蚊子传播亲代病毒。在经口感染并在埃及伊蚊体内复制后,疫苗病毒仍对温度敏感(限制温度为39摄氏度)。

相似文献

1
Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti.登革2型疫苗:在埃及伊蚊中的口服感染、传播及无证据表明病毒在蚊体内回复突变
Am J Trop Med Hyg. 1982 Nov;31(6):1232-7. doi: 10.4269/ajtmh.1982.31.1232.
2
Dengue-2 vaccine: infection of Aedes aegypti mosquitoes by feeding on viremic recipients.
Am J Trop Med Hyg. 1982 Nov;31(6):1229-31. doi: 10.4269/ajtmh.1982.31.1229.
3
Dengue 3 virus infection of Aedes albopictus and Aedes aegypti: comparison of parent and progeny candidate vaccine viruses.
Am J Trop Med Hyg. 1990 Jan;42(1):89-96. doi: 10.4269/ajtmh.1990.42.89.
4
Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.
Am J Trop Med Hyg. 1991 Aug;45(2):202-10. doi: 10.4269/ajtmh.1991.45.202.
5
Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.登革热1型PDK13、登革热3型PGMK30F3和登革热4型PDK48减毒活候选疫苗经埃及伊蚊口服感染后的易感性和传播动力学。
Am J Trop Med Hyg. 1999 Oct;61(4):672-6. doi: 10.4269/ajtmh.1999.61.672.
6
Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.嵌合登革2型疫苗病毒在埃及伊蚊和白纹伊蚊中的生长特性
Am J Trop Med Hyg. 2002 Sep;67(3):260-5. doi: 10.4269/ajtmh.2002.67.260.
7
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.一种减毒活重组登革4型病毒候选疫苗,在蚊子中的传播能力有限,且不会从接种者传播给蚊子。
Am J Trop Med Hyg. 2001 Nov;65(5):414-9. doi: 10.4269/ajtmh.2001.65.414.
8
Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.埃及伊蚊和白纹伊蚊传播登革热病毒活疫苗候选株的可能性有限。
Am J Trop Med Hyg. 2000 Jun;62(6):698-701. doi: 10.4269/ajtmh.2000.62.698.
9
Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.通过实时逆转录聚合酶链反应分析嵌合黄病毒疫苗-登革热1、2、3、4型四价病毒混合物在埃及伊蚊中的复制动力学。
Am J Trop Med Hyg. 2004 Jan;70(1):89-97.
10
Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.
Am J Trop Med Hyg. 1994 Dec;51(6):864-9. doi: 10.4269/ajtmh.1994.51.864.

引用本文的文献

1
Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by .武田四价登革热候选疫苗的传播潜力有限 作者:. (原文此处不完整)
Am J Trop Med Hyg. 2017 Nov;97(5):1423-1427. doi: 10.4269/ajtmh.17-0185. Epub 2017 Aug 18.
2
Vector Competence of American Mosquitoes for Three Strains of Zika Virus.美国蚊子对三株寨卡病毒的媒介能力
PLoS Negl Trop Dis. 2016 Oct 26;10(10):e0005101. doi: 10.1371/journal.pntd.0005101. eCollection 2016 Oct.
3
Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein.
埃及伊蚊感染登革病毒需要一种假定的富含半胱氨酸的毒液蛋白。
PLoS Pathog. 2015 Oct 22;11(10):e1005202. doi: 10.1371/journal.ppat.1005202. eCollection 2015 Oct.
4
Understanding the dengue viruses and progress towards their control.了解登革热病毒及其控制进展。
Biomed Res Int. 2013;2013:690835. doi: 10.1155/2013/690835. Epub 2013 Jul 9.
5
Reduced infection in mosquitoes exposed to blood meals containing previously frozen flaviviruses.接触含有先前冷冻黄病毒的血餐的蚊子感染率降低。
Virus Res. 2007 Nov;129(2):224-7. doi: 10.1016/j.virusres.2007.06.019. Epub 2007 Aug 7.
6
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.登革2型PDK-53病毒作为四价登革疫苗开发的嵌合载体。
J Virol. 2003 Nov;77(21):11436-47. doi: 10.1128/jvi.77.21.11436-11447.2003.
7
Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.嵌合2型登革病毒(疫苗株PDK-53)/1型登革病毒作为1型登革病毒疫苗的潜在候选疫苗。
J Virol. 2000 Apr;74(7):3020-8. doi: 10.1128/jvi.74.7.3020-3028.2000.
8
Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.候选登革2型疫苗病毒16681株(PDK-53)的减毒标记由5'非编码区以及非结构蛋白1和3中的突变所定义。
J Virol. 2000 Apr;74(7):3011-9. doi: 10.1128/jvi.74.7.3011-3019.2000.
9
Titration of dengue viruses by immunofluorescence in microtiter plates.
J Clin Microbiol. 1984 Nov;20(5):1017-9. doi: 10.1128/jcm.20.5.1017-1019.1984.